Jan 22 (Reuters) - NANOBIOTIX SA:
* NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL ANNUAL MEETING
* VERY GOOD SAFETY PROFILE WITH NO AES AND SAES RELATED TO NBTXR3
* THIRD INDICATION IN GLOBAL NBTXR3 DEVELOPMENT CONFIRMING TRANSFERABILITY ACROSS DIFFERENT CANCERS
* ‍COMPLETE RESPONSE ACHIEVED IN 3 OUT OF 7 PATIENTS EVALUABLE​
* ‍PARTIAL RESPONSE ACHIEVED IN 3 OUT OF 7 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 